Skip to main content
. 2018 Jun 8;16(2):2255–2262. doi: 10.3892/ol.2018.8935

Figure 4.

Figure 4.

Kadsurenone directly inhibits RANKL induced osteoclastogenesis. (A) Effect of Kadsurenone on the viability of mouse BMMs. Mouse BMMs were isolated and treated with the indicated concentrations of Kadsurenone. (B) Representative images of Trap+ osteoclasts. Mouse BMMs were isolated and induced for osteoclastogenesis with RANKL (50 ng/ml). Cells were treated with thye indicated concentrations of Kadsurenone and stained on day 7. The (C) number and (D) area of Trap+ osteoclasts per field are indicated (E) Representative images of actin ring staining. Mouse BMMs were isolated and induced for osteoclastogenesis with RANKL (50 ng/ml). Cells were treated with the indicated concentrations of Kadsurenone and stained on day 7. (F) The bar chart represents the mean number of actin rings for three independent experiments. Scale bar, 100 µm. Data are presented as the mean ± standard error of the mean (n=3). P-values were calculated using one-way analysis of variance followed by Tukey's post hoc test. **P<0.01 and ***P<0.001 vs. the control. BMMs, bone marrow monocytes; RANKL, receptor activator for NF-κB ligand; Trap, tartrate-resistant acid phosphatase.